TY  - CHAP
M1  - Book, Section
TI  - Photodynamic Therapy
A1  - Newlove, Tracey
A1  - Anolik, Robert T.
A2  - Geronemus, Roy G.
A2  - Bernstein, Leonard J.
A2  - Hale, Elizabeth K.
A2  - Brightman, Lori A.
A2  - Karen, Julie K.
A2  - Weiss, Elliot T.
A2  - Anolik, Robert T.
Y1  - 2013
N1  - 
T2  - Lasers and Related Technologies in Dermatology
AB  - Throughout  the  20th  century,  scientists  explored  the  use  of  photodynamic  therapy  (PDT)  in  medicine.  PDT  is  a  photochemical  reaction  in  which  a  photosensitizing  molecule,  a  light  source,  and  tissue  oxygen  interact  to  produce  targeted  tissue  destruction.  Although  PDT  was  initially  thought  to  have  great  potential,  its  clinical  use  was  postponed  by  worries  of  prolonged  retention  of  the  photosensitizer.  By  the  late  20th  century,  5-aminolevulinic  acid  (ALA)  was  shown  to  convert  itself  into  an  effective  photosensitizing  molecule,  namely,  protophorphyrin  IX,  in  targeted  tissue  while  also  having  a  reasonable  period  of  tissue  retention.1  This  work  paved  the  way  for  dermatologic  applications.  Topical  PDT  lends  itself  well  to  cutaneous  disease  because  of  the  ease  of  application  of  a  photosensitizer  and  delivery  of  light.  In  1999,  the  Food  and  Drug  Administration  (FDA)  approved  the  use  of  topical  ALA  and  blue  light  for  the  treatment  of  actinic  keratoses  (AK),  and  its  list  of  on-  and  off-label  indications  has  since  continued  to  expand.  
SN  - 
PB  - McGraw-Hill Education
CY  - New York, NY
Y2  - 2024/04/19
UR  - dermatology.mhmedical.com/content.aspx?aid=1175385572
ER  -